| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 468 |
| Gender | Both Genders |
| Age Range | 0-1 |
| Body Types | Average |
Administration of _l. reuteri_ DSM 17938 to infants during the first three months of life greatly reduced the occurrence of infantile colic relative to placebo, and also improve gastrointestinal symptoms such as increasing bowel evacuations (reducing risk of constipation) and regurgitations.
Ultimately, prophylactic treatment of infants with DSM 17938 resulted in less pediatric department visits and was estimated to save both parent and community over $200 (USD).
